Known targets — ChEMBL curated mechanism
823298382338688239847Rdl1Rdl2Rdl3
The experimentally established mechanism targets of Lindane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lindane SCHEMBL8728460 | 0.84 | LMNA (0.39) | LMNACYP3A4GABRA1GABRB1GABRG2 | |
| Lindane SCHEMBL9845655 | 0.76 | LMNA (0.50) | LMNACYP3A4GABRA1GABRB1GABRG2 | |
| SCHEMBL19550 | 0.74 | — | — | |
| SCHEMBL12211325 | 0.74 | — | — | |
| SCHEMBL13716379 | 0.74 | — | — | |
| Lindane SCHEMBL10599867 | 0.73 | LMNA (0.46) | LMNACYP3A4GABRA1GABRB1GABRG2 | |
| Lindane SCHEMBL10416102 | 0.73 | ALDH1A1 (0.55) | LMNACYP3A4GABRA1GABRB1GABRG2 | |
| Methylene Chloride SCHEMBL27388492 | 0.70 | — | — | |
| SCHEMBL6755982 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL15410075 | 0.68 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100254904-A1 | Novel therapeutic delivery systems | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2010-10-07 | — | — | US | claimed |
| US-6479034-B1 | Method of preparing gas and gaseous precursor-filled microspheres | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2002-11-12 | — | — | US | claimed |
| US-20020159952-A1 | Novel acoustically active drug delivery systems | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2002-10-31 | — | — | US | claimed |
| US-6443898-B1 | Therapeutic delivery systems | IMARX PHARMACEUTICAL CORP. | 2002-09-03 | — | — | US | claimed |
| EP-0981333-A4 | NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0981333-A1 | NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-01 | — | — | EP | claimed |
| US-5853752-A | Methods of preparing gas and gaseous precursor-filled microspheres | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-29 | — | — | US | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| WO-1998051284-A1 | NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| EP-0802788-A4 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER EVAN C (US) | 1998-09-09 | — | — | EP | claimed |
| EP-0712293-A4 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0802788-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER, Evan C (US) | 1997-10-29 | — | — | EP | claimed |
| EP-0712293-A1 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER, Evan C (US) | 1996-05-22 | — | — | EP | claimed |
| WO-1994028780-A2 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| WO-1994028874-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| US-20100254904-A1 | Novel therapeutic delivery systems | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-0308981-A2 | An optical information recording medium and its production | Hitachi Maxell Ltd. (JP) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020159952-A1 | Novel acoustically active drug delivery systems | AURKA, AURKC, MTDH | LMNA 1467/4885CYP3A4 536/4885GABRA1 2103/4885 |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | LMNA 3245/4885CYP3A4 2363/4885GABRA1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.